X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ECT204 is an autologous T-cell therapy whereby a subject's T cells are transduced with a lentiviral vector expressing the ECT204 transgene. It is being evaluated for the treatment of adult patients with GPC3-positive advanced hepatocellular carcinoma.
Lead Product(s): ECT204
Therapeutic Area: Oncology Product Name: ECT204
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
The grant will support company's ongoing ARYA-2 Phase I study of ET140203, an autologous T cell-based therapy, for the treatment of pediatric patients with refractory/relapsed liver cancer, including hepatoblastoma, hepatocellular neoplasm not otherwise specified, and HCC.
Lead Product(s): Autologous T Cell-based Therapy
Therapeutic Area: Oncology Product Name: ET140203
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CIRM
Deal Size: $10.6 million Upfront Cash: Undisclosed
Deal Type: Funding June 06, 2023
Details:
Under the licensing agreement, Eureka will develop and commercialize a novel antibody targeting MSLN, a potentially transformative T-cell therapy for solid tumors, in combination with ARTEMIS® T-cell receptor platform.
Lead Product(s): T-cell based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 14, 2023
Details:
The therapy also has expansion potential in medulloblastoma and small cell lung cancer, among several other pediatric and adult cancers that express an abundance of the GPC2 protein on their cell surface.
Lead Product(s): ARTEMIS T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 18, 2022
Details:
ET140203 is an investigational therapy during which a patient’s T cells are collected, engineered to express Eureka’s proprietary ARTEMIS® cell receptor and infused back into the patient.
Lead Product(s): ET140203
Therapeutic Area: Oncology Product Name: ET140203
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
ET140203 T cells are autologous T cells genetically modified to carry a TCR-mimic (TCRm) construct capable of mediating cell killing by targeting tumor specific intracellular antigens and addressing solid tumor therapy challenges.
Lead Product(s): ET140203
Therapeutic Area: Oncology Product Name: ET140203
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
In the study, anti-NDC80 TCRm-redirected T cells demonstrated high specificity in recognizing and killing multiple cancer cell lines. Moreover, no toxicities to healthy leukocytes and hematopoietic stem cells were observed.
Lead Product(s): TCR Mimic CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: NDC80
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Memorial Sloan Kettering Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
The designation for Eureka’s clinical candidate, ET140203, an investigational therapy TCR-mimic antibody to target alpha-fetoprotein peptide/HLA-A2 complex on liver cancer cells underscore the significant unmet medical need for more effective liver cancer treatment options.
Lead Product(s): ET140203
Therapeutic Area: Oncology Product Name: ET140203
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2022
Details:
Newly published study reports Invisimask™, a self-administered nasal spray, protects against Sars-Cov-2 infection for up to 10 Hours in mice.
Lead Product(s): InvisiMask
Therapeutic Area: Infections and Infectious Diseases Product Name: InvisiMask
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2020
Details:
The ARYA-1 study is a multi-center, open-label, dose escalation clinical trial of ARTEMIS® T cell therapy to initially assess the safety and tolerability of ET140203 T cells in adult patients with AFP-positive HCC and to determine the recommended phase II dose (RP2D).
Lead Product(s): ET140203
Therapeutic Area: Oncology Product Name: ET140203
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
